INTERFERON ALFACON-1

Summary

Interferon Alfacon-1 (CHEMBL1201557) is an approved protein (ATC L03AB09); indicated across 5 conditions including chronic hepatitis c virus infection and neoplasm.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Protein
• ATC class: L03AB09
• Indications: 5 conditions
• Clinical trials: 5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201557
Name	INTERFERON ALFACON-1
Type	Protein
Max phase	4
ATC	L03AB09

Also known as: Infergen, Interferon alfacon-1, R-SIFN-CO, Rsifn-co, RSIFNCO, INTERFERON ALFACON-1

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 approved indications. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
chronic hepatitis C virus infection	4	MONDO:0005354	EFO:0004220
neoplasm	4	MONDO:0005070	EFO:0000616

3 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
hepatitis C virus infection	3	MONDO:0005231	EFO:0003047
severe acute respiratory syndrome	2	MONDO:0005091	MONDO:0100096
influenza	1	MONDO:0005812	EFO:0007328

Clinical trials

Total trials: 5.

Phase distribution

Phase	Trials
PHASE1	2
PHASE4	1
PHASE3	1
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00456248	PHASE4	TERMINATED	Infergen and Ribavirin Treatment of Patients With HCV Who Achieved Partial Response to Peginterferon-alfa and Ribavirin
NCT00239252	PHASE3	COMPLETED	Comparison in Efficacy and Safety Between Interferon Alfacon-1 Alone and Concomitant Dosing With Ribavirin for the Treatment of Hepatitis C
NCT01227798	PHASE1/PHASE2	UNKNOWN	Safety and Efficacy Study of Interferon to Treat Patients Hospitalized for Influenza
NCT02387307	PHASE1	COMPLETED	A Study of rSIFN-co in Subjects With Advanced Solid Tumors
NCT02464007	PHASE1	TERMINATED	Study of rSIFN-co for Patients With Advanced Solid Tumors

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).